Evonile Pharma Limited EVONILE
Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.
Loading prices…
Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.Test a strategy on EVONILE
Real prices, every charge counted. Pick one or write your own.Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.
EOD 13 NovThe share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Returns and valuationWhat the market pays for this company and how well the business uses its money.
What the numbers sayShort plain statements about this company's latest figures.
Written by fixed rulesLatest quarterIn the quarter to September 2026 (results filed 3 Nov 2026), sales fell 37.9% from a year earlier to ₹56.0 cr and profit turned to a loss of ₹101 cr from ₹24.2 cr a year earlier.
Nothing in the filings we hold crosses one of our rules yet. Each rule needs a few complete years of results, so recently listed companies often show nothing here.
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
How the share moved on resultsWhat the share price did around each recent quarterly result.
Over the last 3 results, the share rose on 1 and fell on 2, and moved by 3% or more on 2.
Q2 FY27: results filed 3 Nov 2026. The share went from its close on 2 Nov 2026 to its close on 4 Nov 2026 -0.20%.
What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.
Price only, before dividendsHeld for 5 years this compounded at +16.7% a year. The last twelve months were up +168.8%. Price only, before dividends.
At a glanceThe eight figures most people check first, each placed against companies in the same industry.
Against its sectorThe business, year by yearSales and net profit by financial year or by quarter.
Sales and net profitWhere every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.
FY26In FY26, of every ₹100 of sales it kept ₹26.3 as profit. Other income added ₹11.0.
How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.
Compounded a yearHealth check, year by yearMargins, returns and debt for each financial year, so you can see the direction.
| Measure | FY25 | FY26 |
|---|---|---|
| Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax. | 25.7% | 26.6% |
| Net marginOf every ₹100 of sales in the year, how much was left as profit after everything. | 28.3% | 26.3% |
| Interest coverHow many times the company's profit before interest could pay its interest bill. | 164x | 101x |
Each row against this company's own usual level: green better, red worse, grey close to it.
Month by monthThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.
Price return each month| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | +51.0 | -7.8 | +7.2 | +1.1 | +23.5 | -11.8 | +6.8 | · | +75.3% 7m |
| 2023 | -5.5 | -6.3 | -5.7 | +5.6 | +18.7 | +14.7 | -10.8 | -0.8 | +0.4 | -6.7 | · | · | -0.3% 10m |
| 2022 | -4.8 | -14.8 | -6.3 | +6.5 | -6.1 | +3.8 | +18.1 | +1.0 | -6.9 | +0.0 | -1.3 | +0.4 | -13.1% |
| 2021 | -4.4 | -4.9 | -11.3 | +17.6 | +0.6 | +32.5 | +11.2 | -20.0 | +6.2 | -8.9 | +5.1 | -0.8 | +13.4% |
| 2020 | · | · | · | · | · | · | · | · | · | · | +4.1 | +5.0 | +9.3% 2m |
Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.
Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.
No bulk or block deals on record for EVONILE in the window we hold.
Read enough? Test EVONILE. “Buy EVONILE when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.
Run it free